IL9 and myeloid sarcoma: In fact, we found that IL-9 level in the CSF of MS patients inversely correlates with the progression of MS and with the levels of IL-17 observed in the CSF, indicating that inhibition of IL-17 via IL-9 could be protective in MS [118], despite the controversial results on the role of IL-9 in EAE [68, 119].